Karyopharm Therapeutics reported $222.68M in Current Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Amgen AMGN:US USD 22.19B 1.88B
AstraZeneca AZN:LN USD 20.22B 693M
Astrazeneca AZN:US USD 20.22B 693M
Avrobio Inc AVRO:US USD 126.23M 15.85M
Enanta Pharmaceuticals ENTA:US USD 311.71M 1.32M
GlaxoSmithKline GSK:LN GBP 20.77B 520M
Karyopharm Therapeutics KPTI:US USD 222.68M 19.77M
Macrogenics MGNX:US USD 147.81M 19.82M
Mirati Therapeutics MRTX:US USD 1.23B 22.86M
Nektar Therapeutics NKTR:US USD 599.48M 66.05M
Novartis NOVN:VX USD 36.91B 44M
Novartis NVS:US USD 36.91B 44M
Regeneron Pharmaceuticals REGN:US USD 22.06B 6.64B
Roche Holding ROG:VX 30.32B 5.31B
Sangamo Biosciences SGMO:US USD 336.62M 6.5M
Takeda 4502:JP JPY 2.6T 149.67B
Tg Therapeutics TGTX:US USD 182.92M 19.64M
Ultragenyx Pharmaceutical RARE:US USD 1.01B 334.13M
Xencor XNCR:US USD 668M 82.06M
YTE INCY:US USD 3.82B 195.27M